Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PTGX
PROTAGONIST THERAPEUTICS, INC.
NASDAQ
$145.72
▼ DOWN 2.07% (-3.08)

KEY STATISTICS

Market Cap$9.36 B
52w High$160.81
52w Low$54.50
Dividend Yield—
Frequency—
P/E141.48
Volume501.00K
Shares Out.64.31M

COMPANY

LEADERSHIP

Dinesh V. Patel
CHIEF EXECUTIVE
Dinesh V. Patel

COMPENSATION 2026

Salary$715,500
Stock Awards$5,839,204
Incentive Plan Pay$686,880
All Other Comp.$11,912
Total$12,871,506

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 11, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
141

PRICE TARGET

Target High$190.00
Target Low$121.00
Target Median$171.50
Target Consensus$169.38

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$240.13M
NOV
5
THU

PRICE

$145.72 ▼ DOWN 2.07% (−$3.08)
$146$147$1499:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM145.72

About Protagonist Therapeutics, Inc.

https://www.protagonist-inc.com ↗

Protagonist Therapeutics develops peptide-based drugs for blood disorders and inflammatory diseases, with key candidates in Phase II trials and collaborations including Janssen.

INDUSTRY

Biotechnology

A PRODUCT PROTAGONIST THERAPEUTICS, INC. IS KNOWN FOR

Rusfertide
Rusfertide

Rusfertide is an injectable hepcidin mimetic in development for polycythemia vera, with an NDA submitted to the FDA in December 2025, aiming to regulate iron and reduce blood withdrawals in this rare blood cancer.

COMPETITORS

COMPETITOR
INCY COMPARE
IONS COMPARE
MRK COMPARE
NVS COMPARE
SLN COMPARE

Revenue by Products

IconPRODUCTQ1-2024Q2-2024Q3-2024Q4-2024
Development Services$900K $5M ▲$9.7M ▲$4.7M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
228
LISTED HERE
26
RANKED BY POSITION SIZE
XUU.TO
0.01% · 3.7M
VTS.AX
0.01% · 2.1M
AFTY
2.28% · 1.7M
XBI
1.27% · 1.0M
XSMO
2.85% · 578.0K
SCHA
0.19% · 287.3K
FESM
0.24% · 105.3K
JMEE
0.50% · 100.1K
XRSU.L
0.29% · 55.7K
NBDS
4.46% · 55.4K
FTXH
0.68% · 50.2K
USVM
0.35% · 42.1K
LABU
0.83% · 33.4K
RSSL
0.29% · 29.5K
SIXS
1.61% · 16.0K
TQSM.TO
0.28% · 14.3K
LVHB
2.55% · 14.3K
BBP
1.62% · 13.3K
SMIZ
0.62% · 11.6K
GSSC
0.14% · 10.4K
BKMC
0.23% · 10.0K
VAMO
1.08% · 6.4K
DFAC
0.00% · 5.7K
ZSML.TO
0.49% · 5.7K
ISMD
0.24% · 5.5K
EZM
0.08% · 5.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
87.13%
HOLDERS
460
TOP 12 OF 460 · RANKED BY POSITION SIZE
Blackrock, Inc.
10.3M sh · $1.26B
Farallon Capital Management LLC
6.3M sh · $669.17M
Blackrock Inc.
5.8M sh · $199.52M
Rtw Investments, LP
5.8M sh · $382.39M
Vanguard Group Inc
5.4M sh · $472.83M
Ubs Group AG
5.2M sh · $545.74M
Wellington Management Group Llp
3.6M sh · $379.4M
State Street Corp
3.3M sh · $407.16M
Janus Henderson Group Plc
2.9M sh · $304.87M
Bvf Inc/Il
2.6M sh · $170.12M
Johnson & Johnson Innovation - Jjdc, Inc.
2.4M sh · $109.92M
Johnson & Johnson
2.4M sh · $300.22M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets5
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score3

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
PATEL DINESH V PH D
Purchase · 34.2K shares
2026-08-11
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
PATEL DINESH V PH D
Purchase · 65.8K shares
2026-08-10
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
PATEL DINESH V PH D
Sale · 34.2K shares
2026-08-11
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
PATEL DINESH V PH D
Sale · 65.8K shares
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 8
OUTPERFORM 3
OVERWEIGHT 2
MARKET OUTPERFORM 1
14 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT BMO Capital OUTPERFORM HC Wainwright & Co. BUY Citigroup BUY Goldman Sachs BUY Wedbush OUTPERFORM Truist Securities BUY Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
KYMR$117.60COMPARE
CRNX$84.95COMPARE
TGTX$55.84COMPARE
IMVT$39.44COMPARE
ALKS$46.43COMPARE
PTCT$69.86COMPARE
VKTX$34.63COMPARE
NAMS$25.42COMPARE